Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blue Skies: Merck Looks For Chronic Pain Candidates In Australia

This article was originally published in PharmAsia News

Executive Summary

In a deal described as “out of the blue” by Australian biotech Bionomics, Merck has acquired an option to license a small molecule for up to $172 million in fees and milestones as part of a two-year research program focused on chronic pain treatments.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC085045

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel